首页> 美国卫生研究院文献>Oncotarget >Nomograms to estimate long-term overall survival and breast cancer-specific survival of patients with luminal breast cancer
【2h】

Nomograms to estimate long-term overall survival and breast cancer-specific survival of patients with luminal breast cancer

机译:用线照相术估计腔内乳腺癌患者的长期总体生存率和特定于乳腺癌的生存率

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Luminal breast cancer constitutes a group of highly heterogeneous diseases with a sustained high risk of late recurrence. We aimed to develop comprehensive and practical nomograms to better estimate the long-term survival of luminal breast cancer.Patients with luminal breast cancer diagnosed between 1990 and 2006 were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database and randomly divided into the training (n = 87,867) and validation (n = 88,215) cohorts. The cumulative incidence function (CIF) and a competing-risks model were used to estimate the probability of breast cancer-specific survival (BCSS) and death from other causes. We integrated significant prognostic factors to build nomograms and subjected the nomograms to bootstrap internal validation and to external validation.We screened 176,082 luminal breast cancer cases. The 5- and 10-year probabilities of overall death were 0.089 and 0.202, respectively. The 5- and 10-year probabilities of breast cancer-specific mortality (BCSM) were 0.053 and 0.112, respectively. Nine independent prognostic factors for both OS and BCSS were integrated to construct the nomograms. The calibration curves for the probabilities of 5- and 10-year OS and BCSS showed excellent agreement between the nomogram prediction and actual observation. The C-indexes of the nomograms were high in both internal validation (0.732 for OS and 0.800 for BCSS) and external validation (0.731 for OS and 0.794 for BCSS).We established nomograms that accurately predict OS and BCSS for patients with luminal breast cancer. The nomograms can identify patients with higher risk of late overall mortality and BCSM, helping physicians in facilitating individualized treatment.
机译:发光性乳腺癌是一组高度异质性疾病,持续复发的风险很高。我们旨在开发综合实用的列线图,以更好地估计腔内乳腺癌的长期存活率。从监测,流行病学和最终结果(SEER)数据库中检索1990年至2006年诊断为腔内乳腺癌的患者,并将其随机分为训练(n = 87,867)和验证(n = 88,215)队列。累积发病率函数(CIF)和竞争风险模型用于估计乳腺癌特定生存率(BCSS)和其他原因导致死亡的可能性。我们整合了重要的预后因素以构建诺模图,并对诺模图进行内部验证和外部验证。我们筛选了176082例腔内乳腺癌病例。 5年和10年总死亡概率分别为0.089和0.202。乳腺癌特异性死亡率(BCSM)的5年和10年概率分别为0.053和0.112。整合了OS和BCSS的9个独立的预后因素以构建列线图。 5年和10年OS和BCSS概率的校准曲线显示了列线图预测与实际观测之间的极佳一致性。内部验证(OS的0.732和BCSS的0.800)和外部验证(OS的0.731和BCSS的0.794)的诺模图C指数都很高,我们建立了能够准确预测管腔型乳腺癌患者OS和BCSS的诺模图。 。列线图可以识别出晚期总体死亡率和BCSM较高风险的患者,从而帮助医生促进个体化治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号